司库奇尤单抗治疗儿童泛发性脓疱型银屑病临床分析OA

Objective To explore the clinical efficacy and safety of secukinumab in the treat-ment of childhood generalized pustular psoriasis(GPP)in order to provide a new therapeutic strat-egy for childhood generalized pustular psoriasis.Methods A retrospective analysis was conducted on the clinical data of 25 children with GPP treated with subcutaneous secukinumab in our depart-ment from June 2020 to June 2022.The efficacy was evaluated according to Generalized Pustular Psoriasis Physician Global Assessment(GPPGA)scores,Generalized Pustular Psoriasis Area and Severity Index(GPPASI)scores,Children's Dermatology Life Quality Index(CDLQI)scores,and Depression Self-rating Scale for children(DSRSC)scores.The adverse reactions were also assessed.Results Following secukinumab treatments,the average time of lesion clearance was 3.36±0.99 days.Alleviations of scales and pustules were observed in majority of patients after 2-week treatment.After 28-week treatment,GPPGA score was reduced from 3.56±0.50 at baseline to 0.20±0.50,while GPPASI score was decreased from 34.83±9.24 at baseline to 0.68± 1.64.Similarly,both CDLQI and DSRSC scores were decreased 14.96±4.88 to 0.40±0.64 and 11.41±2.54 to 6.64±1.80,respectively.During the course of treatment,upper respiratory tract infections and eczema were observed in 2 cases each.One case each had pain with pruritus on the injection site and headache.No other adverse events were observed.Conclusions Secuki-numab is safe and can rapidly improve the erythema,scales and pustules in pediatric generalized pustular psoriasis in addition to the improvements in patients'quality of life and mental health.